About Bioject
Bioject is a Healthcare company based in Tigard (United States) founded in 1985, and was acquired by Inovio Pharmaceuticals in March 2016. Needle-free injection therapies are developed for medical drug delivery. The company was acqui-hired. Its focus areas include Life Sciences, Drug Delivery and Diversified. Its legal entity is BIOJECT MEDICAL TECHNOLOGIES INC. Its competitors include Ensysce, PharmaJet and Renovis; 3 of its 3 listed competitors have raised funding.
Company details
Bioject Medical Technologies develops needle-free injection therapies (NFITS). The companys technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. The company claims that this creates an ultra-fine stream of fluid that penetrates the skin and delivers medication in a fraction of a second. Products include: Bioject 2000 Needle Free Injection System (to deliver intramuscular injections); ZetaJet (for subcutaneous or intramuscular injections); Drug Reconstitution System (connector to withdraw medication from a vial without using a needle); and Free Vial Adapter (plastic device to replaces a fill needle).
- Headquarters Tigard, United States
- Stage Acquired
- SectorsHealthcare
- Website bioject.com
- Social LinkedIn X
- Acquired by Inovio Pharmaceuticals (Mar 2016)
- Legal Name Bioject Medical Technologies Inc
- Latest Funding Round$994.55K (USD), Post-IPO
Jan 2013
- Investors
- Acquired byInovio Pharmaceuticals
(Mar 2016)
Funding Insights of Bioject
- Total Rounds 7
- Last Round Post-IPO — $994,550
All 7 funding rounds of Bioject with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2013 | $994,550 | Post-IPO | – | – | – |
| Dec 2009 | $1.2M | Post-IPO | – | – | – |
| Sep 2007 | $100,873 | Post-IPO | – | – | – |
| Feb 2007 | Post-IPO | – | – | – | |
| Jun 2006 | $3M | Post-IPO | – | – | – |
| Mar 2006 | $1.5M | Post-IPO | – | – | – |
| Jan 2005 | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Bioject
Bioject has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Inovio Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of vaccines for the treatment of cancer and infectious diseases | 1983 | inovio.com | Plymouth Meeting, United States |
Investor details for Bioject
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Bioject
4 dated milestones of Bioject across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Bioject is founded.
- Funding First funding round.
- Funding Latest funding round, Post-IPO, of $995K.
- Exit Acquired by Inovio Pharmaceuticals.
Competitors of Bioject
Bioject has 3 listed competitors in our database, 3 of them funded. They include Ensysce, PharmaJet and Renovis.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ensysce.com | 2008 | Houston, United States | $2.5M | Drug delivery solutions via single-walled carbon nanotubes are offered. | ||
| pharmajet.com | 2005 | Golden, United States | $59.4M | 15 | Provider of needle-free injection technology | |
| renovis.com | 2000 | San Francisco, United States | $45M | 368 | Drugs for neurological diseases are discovered and developed. |
Detailed competitors of Bioject
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bioject
Websites that share an audience with Bioject (bioject.com).
Websites whose visitors overlap most with Bioject. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmajet.com | 100% | 7.2K | #3,138,582 | View details | |
medcompnet.com | medcompnet.com | 84% | – | ||
| affinitymed.com | 84% | View details | |||
medikraft.com | medikraft.com | 84% | – | ||
chinamedica.com | chinamedica.com | 84% | #14,416,122 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Bioject
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Bioject (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bioject
Bioject was founded in 1985 and raised its 1st funding round 20 years after it was founded.
Bioject is headquartered in Tigard, United States. It is registered at Tigard, Oregon, United States.
Bioject Medical Technologies develops needle-free injection therapies (NFITS). The companys technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. The company claims that this creates an ultra-fine stream of fluid that penetrates the skin and delivers medication in a fraction of a second. Products include: Bioject 2000 Needle Free Injection System (to deliver intramuscular injections); ZetaJet (for subcutaneous or intramuscular injections); Drug Reconstitution System (connector to withdraw medication from a vial without using a needle); and Free Vial Adapter (plastic device to replaces a fill needle).
Bioject has 1 investor. Key investors include Inovio Pharmaceuticals.
Bioject operates through Bioject Medical Technologies Inc.
Yes. Bioject was acquired by Inovio Pharmaceuticals in March 2016.